Literature DB >> 8541169

Effect of low dose sotalol on the signal averaged P wave in patients with paroxysmal atrial fibrillation.

P J Stafford1, J Cooper, D P de Bono, R Vincent, C J Garratt.   

Abstract

OBJECTIVE: To investigate the effects of low dose sotalol on the signal averaged surface P wave in patients with paroxysmal atrial fibrillation.
DESIGN: A longitudinal within patient crossover study.
SETTING: Cardiac departments of a regional cardiothoracic centre and a district general hospital. PATIENTS: Sixteen patients with documented paroxysmal atrial fibrillation. The median (range) age of the patients was 65.5 (36-70) years; 11 were men. MAIN OUTCOME MEASURES: Analysis of the signal averaged P wave recorded from patients not receiving antiarrhythmic medication and after 4-6 weeks' treatment with sotalol. P wave limits were defined automatically by a computer algorithm. Filtered P wave duration and energies contained in frequency bands from 20, 30, 40, 60, and 80 to 150 Hz of the P wave spectrum expressed as absolute values (P20, P30, etc) and as ratios of high to low frequency energy (PR20, PR30, etc) were measured.
RESULTS: No difference in P wave duration was observed between the groups studied (mean (SEM) 149 (4) without medication and 152 (3) ms with sotalol). Significant decreases in high frequency P wave energy (for example P60: 4.3 (0.4) v 3.3 (0.3) microV2.s, P = 0.003) and energy ratio (PR60: 5.6 (0.5) v 4.7 (0.6), P = 0.03) were observed during sotalol treatment. These changes were independent of heart rate.
CONCLUSIONS: Treatment with low dose sotalol reduces high frequency P wave energy but does not change P wave duration. These results are consistent with the class III effect of the drug and suggest that signal averaging of the surface P wave may be a useful non-invasive measure of drug induced changes in atrial electrophysiology.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8541169      PMCID: PMC484120          DOI: 10.1136/hrt.74.6.636

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  22 in total

1.  Signal-averaged electrocardiograms in patients with atrial fibrillation or flutter.

Authors:  T R Engel; N Vallone; J Windle
Journal:  Am Heart J       Date:  1988-03       Impact factor: 4.749

2.  Value of the atrial signal-averaged electrocardiogram in identifying patients with paroxysmal atrial fibrillation.

Authors:  G Opolski; J Stanisławska; K Słomka; T Kraska
Journal:  Int J Cardiol       Date:  1991-03       Impact factor: 4.164

3.  Analysis of high-resolution atrial activation: report on 403 cases.

Authors:  G Baciarello; R Bella; F Di Maio; V Sgrigna; M Villani; S V Campbell; A Sciacca
Journal:  Am Heart J       Date:  1987-02       Impact factor: 4.749

4.  Electrocardiographic features of P waves from patients with transient atrial fibrillation.

Authors:  S Kawano; M Hiraoka; T Sawanobori
Journal:  Jpn Heart J       Date:  1988-01

5.  Rate dependence of sotalol-induced prolongation of ventricular repolarization during exercise in humans.

Authors:  C Funck-Brentano; Y Kibleur; F Le Coz; J M Poirier; A Mallet; P Jaillon
Journal:  Circulation       Date:  1991-02       Impact factor: 29.690

6.  Action of sotalol on potential reentrant pathways and ventricular tachyarrhythmias in conscious dogs in the late postmyocardial infarction phase.

Authors:  S M Cobbe; E Hoffman; A Ritzenhoff; J Brachmann; W Kübler; J Senges
Journal:  Circulation       Date:  1983-10       Impact factor: 29.690

7.  Sotalol in patients with Wolff-Parkinson-White syndrome.

Authors:  K P Kunze; M Schlüter; K H Kuck
Journal:  Circulation       Date:  1987-05       Impact factor: 29.690

8.  Concentration-dependent pharmacologic properties of sotalol.

Authors:  T Wang; R H Bergstrand; K A Thompson; L A Siddoway; H J Duff; R L Woosley; D M Roden
Journal:  Am J Cardiol       Date:  1986-05-01       Impact factor: 2.778

9.  Effect of sotalol on human atrial action potential duration and refractoriness: cycle length dependency of class III activity.

Authors:  R P Hayward; P Taggart
Journal:  Cardiovasc Res       Date:  1986-02       Impact factor: 10.787

10.  Optimal analysis of the signal averaged P wave in patients with paroxysmal atrial fibrillation.

Authors:  P J Stafford; D Robinson; R Vincent
Journal:  Br Heart J       Date:  1995-10
View more
  6 in total

1.  Circadian behavior of P-wave duration, P-wave area, and PR interval in healthy subjects.

Authors:  P E Dilaveris; P Färbom; V Batchvarov; A Ghuran; M Malik
Journal:  Ann Noninvasive Electrocardiol       Date:  2001-04       Impact factor: 1.468

2.  Noninvasive assessment of atrial substrate change after wide area circumferential ablation: a comparison with segmental pulmonary vein isolation.

Authors:  Damian P Redfearn; Allan C Skanes; Lorne J Gula; Michael J Griffith; Howard J Marshall; Peter J Stafford; Andrew D Krahn; Raymond Yee; George J Klein
Journal:  Ann Noninvasive Electrocardiol       Date:  2007-10       Impact factor: 1.468

3.  Prediction of the recurrence of atrial fibrillation after successful cardioversion with P wave signal-averaged ECG.

Authors:  Marco Budeus; Marcus Hennersdorf; Christian Perings; Heinrich Wieneke; Raimund Erbel; Stefan Sack
Journal:  Ann Noninvasive Electrocardiol       Date:  2005-10       Impact factor: 1.468

4.  The P Wave Time-Frequency Variability Reflects Atrial Conduction Defects before Paroxysmal Atrial Fibrillation.

Authors:  Raúl Alcaraz; Arturo Martínez; José J Rieta
Journal:  Ann Noninvasive Electrocardiol       Date:  2014-11-23       Impact factor: 1.468

5.  Effects of right coronary artery PTCA on variables of P-wave signal averaged electrocardiogram.

Authors:  Marco Budeus; Marcus Hennersdorf; Stefan Dierkes; Michael Preik; Matthias P Heintzen; Malte Kelm; Christian Perings
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-04       Impact factor: 1.468

6.  High-resolution analysis of the surface P wave as a measure of atrial electrophysiological substrate.

Authors:  Damian P Redfearn; Joanne Lane; Kevin Ward; Peter J Stafford
Journal:  Ann Noninvasive Electrocardiol       Date:  2006-01       Impact factor: 1.468

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.